Paclitaxel and Pazopanib in Ovarian Cancer-Reply

Affiliations

¹ Section of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma, Oklahoma City.
² University of Texas, MD Anderson Cancer Center, Houston.
³ NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Buffalo, New York.

Comment

Debra L Richardson et al. JAMA Oncol. 2018.

. 2018 Sep 1;4(9):1299.

doi: 10.1001/jamaoncol.2018.1712.

¹ Section of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma, Oklahoma City.
² University of Texas, MD Anderson Cancer Center, Houston.
³ NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Buffalo, New York.

No abstract available

Comment on

Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL, Sill MW, Coleman RL, Sood AK, Pearl ML, Kehoe SM, Carney ME, Hanjani P, Van Le L, Zhou XC, Alvarez Secord A, Gray HJ, Landrum LM, Lankes HA, Hu W, Aghajanian C. Richardson DL, et al. JAMA Oncol. 2018 Feb 1;4(2):196-202. doi: 10.1001/jamaoncol.2017.4218. JAMA Oncol. 2018. PMID: 29242937 Free PMC article. Clinical Trial.
Paclitaxel and Pazopanib in Ovarian Cancer.
Tomao F, Benedetti Panici P, Tomao S. Tomao F, et al. JAMA Oncol. 2018 Sep 1;4(9):1298-1299. doi: 10.1001/jamaoncol.2018.1695. JAMA Oncol. 2018. PMID: 29978181 No abstract available.